Scientific resources

Scientific publications

Service
18/02/2022

Exosome-mediated genetic reprogramming of tumor-associated macrophages by exoASO-STAT6 leads to potent monotherapy antitumor activity

Published in Science Advances: the preclinical development program of exoASO-STAT6, a novel, engineered #exosome precision medicine candidate for the treatment of macrophage-rich tumors.

A.I
06/01/2022

OncoSNIPE® Study Protocol, a study of molecular profiles associated with development of resistance in solid cancer patients

Early/ late resistance marker; Immunological profile; NGS; Non small-cell lung cancer; Pancreatic ductal adenocarcinoma; Triple negative breast or Luminal Breast Cancer.

Service
11/12/2021

Synergistic Interferon-Alpha-Based Combinations for Treatment of SARS-CoV-2 and Other Viral Infections

SARS-CoV-2; antiviral drug combination; hepatitis C virus; hepatitis E virus; human immunodeficiency virus; influenza A virus; interferon-alpha.

Service
04/09/2021

Nafamostat–Interferon-α Combination Suppresses SARS-CoV-2 Infection In Vitro and In Vivo by Cooperatively Targeting Host TMPRSS2

SARS-CoV-2; interferon-alpha; nafamostat; antiviral drug combination; broad-spectrum antivirals

Service
04/09/2021

Nafamostat-Interferon-α Combination Suppresses SARS-CoV-2 Infection In Vitro and In Vivo by Cooperatively Targeting Host TMPRSS2

SARS-CoV-2; antiviral drug combination; broad-spectrum antivirals; interferon-alpha; nafamostat.

Biotech
12/06/2021

Inhibiting Endothelial Cell Function in Normal and Tumor Angiogenesis Using BMP Type I Receptor Macrocyclic Kinase Inhibitors

Inhibiting Endothelial Cell Function in Normal and Tumor Angiogenesis Using BMP Type I Receptor Macrocyclic Kinase Inhibitors

Service
19/05/2021

Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models

Exploring the Complementarity of Pancreatic Ductal Adenocarcinoma Preclinical Models

Service
22/04/2021

ExoSTING, an extracellular vesicle loaded with STING agonists, promotes tumor immune surveillance

Read in Communication Biologics (Nature), the data from the exoSTING preclinical program, in which Oncodesign participated (Hepa1-6).

Service
01/04/2021

Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models

Antitumor Activity of Eribulin After Fulvestrant Plus CDK4/6 Inhibitor in Breast Cancer Patient-derived Xenograft Models

Service
12/02/2021

Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection

Human ACE2 peptide-mimics block SARS-CoV-2 pulmonary cells infection